| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -2,050 | -3,160 | -4,130 | -5,610 | -4,020 |
| Net Income Growth | +35.13% | +23.49% | +26.38% | -39.55% | -17.20% |
Fluoropharma Medical Inc (FPMI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
FluoroPharma Medical, Inc. is engaged in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company's initial focus is the development of positron emission tomography imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer's disease and agents for detection of certain types of cancer. FluoroPharma Medical, Inc. is headquartered in Boston, Massachusetts.
Fiscal Year End Date: 12/31